A Forward Look into The Year Ahead - Research Report on Warner Chilcott Plc., Endo Health Solutions Inc., The Western Union Company, Euronet Worldwide, Inc. and The Procter & Gamble Company

Tue Mar 12, 2013 8:02am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


NEW YORK,  March 12, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Warner
Chilcott Plc. (NASDAQ: WCRX), Endo Health Solutions Inc. (NASDAQ: ENDP), The
Western Union Company (NYSE: WU), Euronet Worldwide, Inc. (NASDAQ: EEFT) and The
Procter & Gamble Company (NYSE: PG). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Warner Chilcott Plc. Research Report

After separating from Warner-Lambert in 1996,  Warner Chilcott  has evolved to
become a fully integrated pharmaceutical company with a broad portfolio of
leading branded products. However, Wall Street has not been kind to  Warner
Chilcott  in the past year. It had put itself on sale early in 2012, much to
investors' delight, but dropped the sale in August. To make matters more
difficult,  Warner Chilcott's  acne treatment drug Doryx is facing generic
competition, while Enablex and oral contraceptive Loestrin could both lose their
patents by 2015. Nevertheless, Warner Chilcott CFO  Paul Herenden  comments that
the company still has strong strategies for its key franchises. Herendeen
asserted that the company is working on improved versions of its existing
products and are developing new products such as a Phase 2 product for rosacea
and acne, and a Phase 3 treatment for erectile dysfunction. The Full Research
Report on Warner Chilcott Plc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


Endo Health Solutions Inc. Research Report

The patents on Lidoderm patch and Opana ER tablets are due to expire. Lidoderm
had sales of  $825 million  in 2011 and this accounted for 30 percent of the
company's revenues.

Furthermore, with more deaths arising from painkiller overdose, regulators have
been looking more closely on how painkiller manufacturers have been handling
their products. The company is setting aside  $194 million  to cover possible
penalties because of a federal investigation into how the company promoted and
sold its Lidoderm patch painkilling drug. The Full Research Report on Endo
Health Solutions Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


The Western Union Company Research Report

As the largest global money movement and payment services company, Western Union
gets its revenues from charging fees to transfer money all over the world. The
company's large size, solid balance sheet, and sustainable pricing power give it
a strong competitive advantage over its rivals. This advantage allows Western
Union to match competitors' pricing pressures, and prevent new businesses from
forming. Western Union is one of the best examples of companies today with wide
economic moats that are trading at discounts to their intrinsic values. In an
attractive industry, the company's dominant market share allows significant cost
and network advantage. It also has operating margins about twice the size of its
competitors. Trading at a substantial discount provides the company strong
protection against downside risk, and provides a good chance at earning high
returns. As the industry consolidates, Western Union has opportunity to grow
through both increased market share and expansion into new markets. The company
recently ventured into prepaid cards, providing significant growth opportunities
playing to its strength of wide distribution. Despite its stock losing about a
quarter of its value in 2012, Western Union offered a good 3.70 percent dividend
yield. The company also approved a new share repurchase program of  $550
million. These initiatives can help strengthen investors' confidence in the
stock. Shares of Western Union traded up 3.40 percent on Monday, hitting 
$13.99. In the previous quarter, the company has reported  45 cents  EPS,
meeting analysts' expectations. Analysts have issued a buy rating with a  $12 to
$19  price target. Continuing to build upon its global agent network, it
recently announced the expansion of its Direct-to-Bank service to include  China
 and  Canada. Q1 2013 results will be released on  April 22, 2013. The Full
Research Report on The Western Union Company - including full detailed
breakdown, analyst ratings and price targets - is available to download free of
charge at: [http://www.Investors-Alliance.com/r/full_research_report/3b71_WU]


Euronet Worldwide, Inc. Research Report

Euronet focuses on expanding its global network. The company has recently
announced the acquisition of Pure Commerce, an  Australia-based company offering
cloud-based financial and payment solutions. The acquisition would allow Euronet
to expand its services and operating markets. The company expects the
acquisition to contribute approximately  three to four cents  to its annual cash
EPS in 2013. On  February 15, 2013  it will release its Q4 2012 earnings
results. With migration from developing to developed countries increasing,
remittances are becoming more relevant for all major developing economies in the
world. The Full Research Euronet Worldwide, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free of
charge at: [http://www.Investors-Alliance.com/r/full_research_report/3c52_EEFT]


The Procter & Gamble Company Research Report

P&G, the world's largest consumer goods producer, recently reported impressive
results for the last three months of 2012, or Q2 2013. The company earned  $4.1
billion, up from  $1.7 billion  earnings during the same quarter in the previous
fiscal year. The impressive results are driven by the company's cost-cutting
efforts as well as the introduction of new products, including Tide Pods and a
new version of the Pantene shampoo. Gaining 1.8 percent in 2012, P&G stands a
better chance of performing better in 2013 than its rivals, including
Colgate-Palmolive. Due to strategic pricing, the company's sales are increasing.
In the long term, it is aiming to increase sales volume while maintaining higher
prices. P&G owns some of the best brands in the world that are known for trust
and quality, allowing it to charge a premium for its products. Looking ahead,
P&G expects to experience stable growth in 2013. The company repurchased  $1.4
billion  in stock in the latest quarter, totaling of  $4 billion  worth of
repurchases since  July 2012. P&G expects to repurchase  $6 billion  by June. Q3
2013 earnings of P&G are tentatively scheduled to be released on  April 24,
2013. The Full Research Report on The Procter & Gamble Company - including full
detailed breakdown, analyst ratings and price targets - is available to download
free of charge at:


Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email:  press@investors-alliance.com 

Main: +1-(408)-745-7826

SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.